Icagen — Taglich Conference 2016
14 slides from Icagen's conference presentation, May 3, 2016
Slide 1: Advancing Ion Channel & Transporter Discovery
CAGEN ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY Taglich Conference May 3, 2016 (©2015 ICAGEN
Slide 2: Advancing Ion Channel & Transporter Discovery
™ ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY As a leading drug discovery services company, Icagen brings a unique approach and deep experience in the ion channel field, now enhanced by the XRpro® platform, to offer industry-leading novel drug discovery and biomarker development capabilities to ph
Slide 3: Forward Looking Statement
Forward Looking Statement ICAGEN Lee Certain statements in this presentation relating to Icagen, Inc. (“icagen ’) contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking Statements are
Slide 4: Leadership Team
Leadership Team ICAGEN Tim Tyson Chairman of the Board 35+ yrs biopharma leadership BMS, GSK, Valeant, Aptuit (©2015 ICAGEN Richie Cunningham President & CEO 20+ yrs healthcare industry leadership Premier Inc., Valeant, Boehringer- Ingelheim Doug Krafte Chief Scientific Officer 25+ yrs biotech & pha
Slide 5: Pharmaceutical Services Outsourcing Market
Pharmaceutical Services Outsourcing Market ICAGEN Lee Outsourcing * Well documented patent Outsourcing Segments cliff challenges for Pharmaceutical Companies * Pharmaceutical Companies are ina state of restructuring and transition —_ Discovery > + Development » + Commercialization > * The trends for
Slide 6: Our Space - Drug Discovery Segment
Our Space - Drug Discovery Segment ICAGEN Lee Outsourcing Drug Discovery Drug Discovery Outsourcing as a Macro Trend — Market Overview * Greater comfort to outsource drug Annual Growth Rate Of 13.3% between discovery is growing 2014 and 2019 29.7 27.4 * Move from fixed to 21.8 variable cost model ch
Slide 7: Opportunistic Acquisition: History & Evolution
Opportunistic Acquisition ICAGEN (©2015 ICAGEN History & Evolution Biotech Heritage Developing Molecules to take into the clinic @, 1992 dey 1999 DB) 2007 (Pfizer) 2017 pesos leagen enters intodug ase completes esp ine toned Fiat icagenlonchanel,—igcoverycalboraton with acuistonofleagen and te ascov
Slide 8: Opportunistic Acquisition
Opportunistic Acquisition ICAGEN Lee XRprosciences » ICAGEN July 2015 lon Channel/ Transporter Contract Research Organization Combining 20 years of expertise along with unique technology capabilities ICAGEN This capability will enable us to understand the full potential of XRpro® while capitalizing
Slide 9: Our Business
Our Business ICAGEN as me S o= ESB =D SS DEDsE» Early Stage of Drug Discovery Multiple therapeutic opportunities CNS , CardioPulmonary CardioMetabolic Cell line development Assay development Oncology = Immunology A Data Generation (©2015 ICAGEN
Slide 10: Commercial Update
Commercial Update ICAGEN eee 7 Purchase Orders 4800000 Large Pharma Clients 4420000 s.0m000 4 200000 J | seoomn0 Biotech Clients 0000 200000 s a a 3 as 2 Government Grants Number of Programs 16 On-going Programs 1 4.7 7 Million in PO’s (2016) 2 | - a Jan Feb Mar : (©2015 ICAGEN 40
Slide 11: Projections
Projections ICAGEN ——————— 3 Year Projection $60,000,000 Revenue 12-50M $50,000,000 $40,000,000 $30,000,000 $20,000,000 $10,000,000 S$. 2014 2015 2016 2017 2018 2016 Projections $6-11M (©2015 ICAGEN oT
Slide 12: Private Placement Update & Trading
Private Placement Update & Trading ICAGEN Lee * In December 2015 Gross proceeds - $8.855 million and net proceeds - $8,109 million were raised — 1.265 million units at $7.00 per unit, (four common shares and one five year warrant for common share exercisable at $1.75) through Taglich Brothers — A to
Slide 13: Summary
Summary ICAGEN eEEEE——————eeeee * Recognized leader in lon Channel Market « Market is strong and growing * Outsourcing is increasing faster than market growth * Expecting cash flow breakeven to occur in 2016 * Expect continued company growth based on these dynamics Actively looking at additional syn
Slide 14: Questions
CAGEN ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY Questions (©2015 ICAGEN